BCA101 + Pembrolizumab for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing BCA101, a new drug that targets specific cancer growth proteins, in patients with advanced cancers that haven't responded to other treatments. The drug works by blocking proteins that help the cancer grow and spread.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications. However, you cannot be on certain treatments like corticosteroids above a specific dose or certain antiviral therapies. It's best to discuss your current medications with the trial team.
Is the combination of BCA101 and Pembrolizumab safe for humans?
What makes the drug BCA101 + Pembrolizumab unique for cancer treatment?
BCA101 (Ficerafusp Alfa) combined with Pembrolizumab is unique because it targets specific proteins involved in cancer growth and immune response, potentially offering a novel approach compared to standard treatments. Pembrolizumab is known for blocking PD-1, a protein that helps cancer cells evade the immune system, while BCA101 may have additional mechanisms that enhance this effect.16789
What data supports the effectiveness of the drug BCA101 + Pembrolizumab for cancer?
Are You a Good Fit for This Trial?
This trial is for patients with advanced solid tumors driven by EGFR, such as certain types of anal, head and neck, lung cancers, and more. Participants must have tried some treatments already without success or been unable to tolerate them. They should be relatively healthy otherwise (performance status ≤1) and willing to undergo tumor biopsies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of BCA101 monotherapy or BCA101 in combination with pembrolizumab to determine the maximum tolerated dose
Expansion Cohorts
Participants receive treatment at the recommended dose in select tumor types to further evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BCA101
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bicara Therapeutics
Lead Sponsor
Merck Sharp & Dohme LLC
Industry Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University